Integrating Services Across the Full Spectrum of Cell and Gene Therapy

February 11, 2022 PAO-02-22-R250-10

On the Road to 50 States, Jennifer Chadwick, Vice President of Analytical Development at BioAnalytix (now ProtaGene), talks to Nigel about how the merger of the companies allows them to perform an integrated service function across the full spectrum of what’s needed for gene and cell therapy development.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

ProtaGene

ProtaGene is a world leading CRO partner for the biopharmaceutical and gene and cell therapy industries. From discovery to product commercialization, ProtaGene provides the most advanced, integrated, and complete protein and gene analytic capabilities and packages for biologic therapeutics and cell & gene therapy platforms. A unique combination of protein- and gene-based analytical platforms make ProtaGene the leading analytic service provider in biologics and cell & gene therapy development. The organization operates four sites in Europe and North America and works in advanced therapeutic platforms with leading biopharmaceutical and gene therapy companies worldwide. Additional information is available at www.protagene.com.

Q: